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Leading Opinion
Implementing the Proclamation of
Stroke and Potentially Preventable
Dementias
Vladimir Hachinski1 , Detlev Ganten2, Daniel Lackland3,
Reinhold Kreutz4, Konstantinos Tsioufis5 and Werner Hacke6; on
behalf of the World Stroke Organization, the World Heart
Federation, the World Hypertension League and the European
Society of Hypertension
Abstract
Brain health plays a central role in wellbeing and in the management of chronic diseases. Stroke and dementia pose the
two greatest threats to brain health, but recent developments suggest the possibility that preventing stroke may also
prevent some dementias: 1. A large population study showed a 32% decrease in the incidence of stroke and a concomi-
tant 7% reduction in the incidence of dementia; 2. Treatment of atrial fibrillation resulted not only in stroke reduction,
but a 48% decrease in dementia; 3. A hypothesis free analyses has shown that the first phase of Alzheimer disease
involves vascular dysregulation, opening the door to new therapeutic approaches; 4. Cognitive impairment, often treat-
able and reversible, accompanies heart and kidney failure. These developments, combined with the knowledge that
stroke, dementia and heart disease share the same major treatable risk factors, particularly hypertension, offers an
opportunity for their joint prevention.
This aspiration is expressed by a Proclamation of the World Stroke Organization on Stroke and Potentially
Preventable Dementias and endorsed by the World Heart Federation, the World Hypertension League, Alzheimer
Disease International and 18 other international, regional and national organizations as a call for action.
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Introduction
Without a healthy brain little else is worthwhile, and
without brain health there is no health. In the era of
growing chronic non-communicable diseases (NCDs),
cognitive competence plays a crucial overarching role
in prevention, treatment and rehabilitation of almost
all NCDs.
Background
Specialization has created two expanding and divergent
fields: stroke and dementia; and yet, stroke and demen-
tia often occur together, pose risks for each other1 and
vascular and neurodegenerative pathologists interact
additionally and synergistically, even in asymptomatic
individuals.2
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In principle, 90% of strokes3 and about 35% of
dementias4 are preventable. Stroke and dementia stat-
istics are usually studied in isolation and the fact that
stroke doubles the chances of developing dementia5 is
frequently ignored when calculating the percentage of
potentially preventable or even reversible dementias.
If this fact is considered, the true number of potentially
preventable dementias would be higher than the
assumed, since stroke and dementia share the same
risk factors6 and given that stroke is more common
than dementia worldwide, at least half of dementias
should be preventable in principle.
Other NCDs such as chronic heart failure, chronic
kidney disease, diabetes and hypertension can be accom-
panied by cognitive decline and dementia, which again
may be treatable and in some cases, with treatment of
the underlying condition (e.g. kidney transplantation)
even reversible. In this context diabetes and hypertension
play a special role because they are on one hand import-
ant risk factors for the development of stroke, heart fail-
ure and chronic kidney disease, and on the other hand
can be linked to cognitive impairment without having
caused a stroke yet.7–11
Challenges
Two common conditions remain below the threshold of
awareness of many physicians.
Little strokes, big trouble
The commonest outcome of cerebrovascular disease is
not clinical stroke, but cognitive impairment.
Asymptomatic cerebral infarcts outnumber symptom-
atic one in a ratio about 5:1 and result in subtle neuro-
logical signs, cognitive impairment and a decrease in
processing speed.12
Cerebral infarcts can cause not only damage by
themselves, but can trigger inflammation and can
kindle neurodegeneration.13 Similarly, asymptomatic
cerebral hemorrhages may cause, contribute or trigger
cognitive decline. The realization that multiple little
asymptomatic strokes can amount to major cognitive
impairment prompted the World Stroke Day warning
theme for 2008 ‘‘Little Strokes, Big Trouble’’.14
Organ failure and brain failure
All failures of major organs lead to different degrees of
cognitive impairment. Heart failure constitutes the
most prevalent.15–19 Kidney failure represents another
common example, the cognitive status often fluctuating
with the dates of dialysis.
In each case, the mechanisms vary, but typically the
focus is on the primary organ affected with relatively
little research being done on the cognitive consequences
and the role that brain itself may play.
Risk factors
Common risk factors
Stroke and dementias share almost the same risk factors.
This holds true for dementias that would fall under the
common term of vascular dementias, but also for degen-
erative dementia of the Alzheimer disease spectrum
(Table 1) (Solomon 2014). The same applies to the
common forms of heart, kidney and retinal disease.20
Hypertension
Hypertension emerges as the most prevalent and treat-
able risk factor. The beneficial effects of treating hyper-
tension in preventing heart disease and stroke are
well established and empirical evidence suggests that
treating hypertension benefits cognition.21 However,
the optimal blood pressure for the brain remains to
be determined. Part of the difficulty stems from the
short duration of the clinical trials.22 Moreover, a
number of blood pressure parameters relevant to the
brain have not been addressed systematically. Pulse
pressure relates to arterial brain stiffness23,24 which in
turn correlates with brain perfusion, which itself may be
heterogenous25 requiring different blood pressure par-
ameters. One of the strongest associations between
hypertension and the brain relate to white matter
changes (leukoaraiosis) that in turn represent harbin-
gers of increased risk for stroke and dementia.26
However, these white matter changes may have differ-
ent origins. The brunt of hypertension associated
infarcts, hemorrhages and white matter changes occur
in the core of the brain, which one of us (VH) has called
‘‘the vascular centrecephalon’’27 and renamed ‘‘ances-
tral brain’’, a high blood pressure system. In contrast,
the ‘‘homo sapiens brain’’ (the enormous growth of the
cerebral hemispheres, especially white matter) represents
a low blood pressure system. By the time that the
branches deriving from the Circle of Willis, round the
hemisphere and the send branches to the depth of hemi-
spheric white matter, the perfusion pressure is low.
A group modeling the cerebral circulation has calculated
that when the brachial blood pressure is 117/75, it is 113/
73 in the ancestral brain and 59/38 in the sapiens brain.28
In practical terms, it means that the optimal blood pres-
sure for controlling the risk of infarcts, hemorrhages and
leukoaraiosis may be too low for the homo sapiens brain
resulting in subtle cumulative hypotensive damage.
To determine the best level of blood pressure control
for the individual may require determining cerebral
blood flow autoregulation.
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Diabetes
Along with the expanding statistics about obesity
comes the increased risk of diabetes. The brain conse-
quences of diabetes have been long established, but the
mechanisms remain obscure.29,30
Homocysteine
The association of high homocysteine levels and vascu-
lar risk leaves little doubt. Controversy still remains
about treating high levels, however the evidence is
slowly tipping the scales towards prevention.31
Other treatable and potentially preventable
dementias
In addition to the above, a number of dementias of
various etiologies are treatable and manageable to dif-
ferent degrees. These include toxic, metabolic, infec-
tious, brain and systemic inflammatory, antibody,
neoplastic and hydrocephalic disorders.32
The important point is that cognitive disorders are
more common than detected and more treatable and
potentially preventable than realized.33
Cerebrovascular disease as a trigger
for neurodegeneration
Experimentally even a small cerebral infarct can pro-
duce extensive, mainly white matter inflammation and
cognitive impairment and after a stroke, white matter
inflammation correlates better with cognitive status at
6 months than the initial cognitive status.13
Longitudinal studies suggest that in the elderly one
quarter have asymptomatic cerebrovascular disease,
another quarter have symptomless Alzheimer path-
ology, but the combination double the chances that
an individual will develop dementia.34
A hypothesis free, data driven analysis of the
Alzheimer Disease Neuroimaging Study (ADNI) iden-
tified the first pathological biomarkers in Late Onset
Alzheimer Disease (LOAD) were vascular dysregula-
tion, a surprising and promising finding.35
Recent developments
Growing population, clinical and pathophysiological
data compel new actions and approaches to the joint
prevention of stroke and dementia.
Population studies
Concomitant with a successful stroke strategy, the age-
specific incidence of stroke and of dementia in Ontario
(population 14 million) dropped by 32% and 7%,
respectively, over a 12 year period.36 Based on this
and other evidence a Proclamation calling for the
joint prevention of stroke and dementia was launched
in 2015, sponsored by the World Stroke Organization
and endorsed by Alzheimer Disease International, the
World Heart Federation, the World Hypertension
League and all the major international, regional and
some national organizations dealing with the brain,
stroke and dementia.37
Clinical studies
The FINGER Study showed for the first time that mul-
tiple lifestyle interventions can result in cognitive
improvement among individuals at risk of developing
dementia, even when they are APOe4 positive.38
A Swedish study involving 444,106 patients with
atrial fibrillation showed that anticoagulation decreases
the risk of dementia by 48%.39
Opportunities
The World Health Summit
The World Health Summit is sponsored by Angela
Merkel, Emmanuel Macron and Jean-Claude Junker
of the European Commission. The aim is to improve
health all over the planet, catalyzing that process
through collaboration and open dialogue, and steering
tomorrow’s agenda to improve research, education,
healthcare, and policy outcomes.
It brings together researchers, physicians, key gov-
ernment officials, and representatives from industry as
well as from non-government organizations (NGOs)
and healthcare systems all over the world to address
the most pressing issues facing every facet of healthcare
and medicine in the upcoming decade and beyond.
The World Health Summit is built on the stable
foundation of academic freedom and excellence pro-
vided by the M8 Alliance and has strong political sup-
port from a variety of partners at global, national and
state levels.
The prevention of cardiovascular disease requires
an interdisciplinary approach. The World Stroke
Organization, World Heart Federation and the World
Hypertension League, together with other stakeholders,
have established an innovative partnership approach
focused on collective advocacy towards Ministries of
Health to implement evidence based interventions in
secondary, primary and primordial prevention of circu-
latory disease.40 All these organizations are uniquely
positioned to address the various components that
determine circulatory health, and this strong collabora-
tion will produce synergistic results to benefit all our
patients.41,42,43 This united effort in the joint prevention
International Journal of Stroke, 13(8)
782 International Journal of Stroke 13(8)
of stroke and dementia, building on the larger frame-
work and achievements of better blood pressure con-
trol43 and continued advances in cardiovascular disease
prevention44,45,46 would finally also affect prevention of
vascular dementias.
The pessimism arising from the growing list of failed
trials in cognitive impairment and dementia pursing the
amyloid/tau hypothesis is countervailed by the increas-
ing evidence that by preventing stroke, we can begin
preventing some dementias now.
Figure 1. Logos of the organizations endorsing the Proclamation.37
Table 1. Main proposed common risk and protective factors for stroke and dementia
Non- Modifiable Modifiable
Risk factors Risk factors Protective factors
Advanced age Cerebrovascular disease/Stroke High education
Genetic factors (Apo E4) Cardiovascular diseases Physical activity




Atrial fibrillation Anticoagulant medications*
Smoking Cessation*




Modified from Solomon A. . ...Kivipelto M. et al.6
International Journal of Stroke, 13(8)
Hachinski et al. 783
The number of individuals trying to understand the
interaction of stroke and dementia and try and prevent
them together is still small enough that most of them
will be able to gather in Berlin in October 13-14, 2018
to highlight what is known and what needs to be done
next. A one day Satellite meeting scheduled for
Saturday, October 13th has been organized that will
also be the background for the main conclusions at
the World Health Summit itself. https://www.registra-
tion-whs.com/Program/WHS2018. Following the meet-
ing, a manuscript summarizing the main findings will be
published. It covers pathophysiology, epidemiology,
clinical aspects with an emphasis on dementia preven-
tion by stroke prevention.
A workshop has also been organized for Sunday,
October 14th at the World Health Summit on the
theme of ‘‘Preventing dementia by preventing stroke’’
that summarizes the main findings and recommendations.
https://www.worldhealthsummit.org/satellites/dementia-
stroke-prevention.html.
All of the organizations endorsing the Proclamation
have been asked to publicize the meetings, to send
delegates and to participate in developing an action
agenda.
Conclusions
The new opportunities becoming evident by investigat-
ing the broader picture of health and disease including
comorbidities such as stroke and dementia confirm the
philosophy of the M8 Alliance and the World Health
Summit that health is much more than increasingly
specialized medicine. We need a holistic view on
health and disease. Comorbidities need to be looked
at closely with respect to their interdependence.
Stroke and dementia are thus an important example
for this comprehensive holistic approach, ever more
needed in the aging societies in all countries around
the world.
If we want to make progress, improve health and
prevent disease on a global level, the example of
hypertension, cardiovascular disease, stroke and
dementia teaches us an important lesson also in
other areas of medicine. The aims of the coalition
for vascular health and the program of the World
Health Summit therefore includes cutting edge science
and the translation to clinics, public and global health
and the aim is to discuss problems and solutions with
stakeholders from academia, the private sector politics
and civil society. We believe that the possibilities of
preventing and treating widespread diseases such as
hypertension, stroke and dementia provide an import-
ant example on what can be achieved based on already
existing evidence. We have to take responsibility and
call for action.
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